Bremelanotide is the molecule. Vyleesi is the FDA-approved branded autoinjector that contains it, approved only for acquired, generalized low sexual desire (HSDD) in premenopausal women. Compounded PT-141 is the same active molecule prepared by a licensed pharmacy for one patient's prescription: it is not FDA-approved, and use outside the Vyleesi indication, including in men, is off-label.
Search for bremelanotide and you get three names used as if they were interchangeable. They point at the same active ingredient, but they are not the same product, they do not carry the same regulatory status, and you do not get them the same way. This guide sorts out which is which, who each one is meant for, and how each is obtained.
Bremelanotide, Vyleesi and PT-141: three names, three meanings
If you searched "what is pt141" or "pt141 bremelanotide", here is the short decode:
- Bremelanotide is the generic name of the active molecule: a synthetic melanocortin receptor agonist that acts on MC3R and MC4R receptors in the brain. It is not a blood-flow (PDE5) drug and does not work like Viagra or Cialis.
- PT-141 is the code name bremelanotide carried during development. Today it is mostly used for compounded preparations and, less helpfully, for unregulated "research" vials sold online.
- Vyleesi is the brand name of one specific finished product: a 1.75 mg single-dose subcutaneous autoinjector, approved by the FDA in 2019.
Think of it as the difference between an ingredient and a finished, labelled medicine. The ingredient is shared. Everything around it, from the dose form to the label to the oversight, can differ. For the receptor science in more depth, see what is PT-141 and how bremelanotide works.
Bremelanotide vs Vyleesi vs compounded PT-141: side by side
A fourth column is included because "research-grade PT-141" shows up in the same search results and is a very different thing.
| Vyleesi | Compounded PT-141 | "Research-grade" PT-141 | |
|---|---|---|---|
| What it is | Branded, FDA-approved bremelanotide autoinjector | Bremelanotide prepared by a licensed pharmacy for a named patient | Powder or vials sold as "not for human use" |
| FDA status | FDA-approved (2019) | Not FDA-approved | Not approved, not a prescription product |
| Approved use | Acquired, generalized HSDD in premenopausal women only | None. Any use is off-label, at a prescriber's discretion | None |
| Men | Label says not indicated in men | Off-label, only if a provider judges it appropriate | Not a legitimate option |
| Form | 1.75 mg single-dose autoinjector | Subcutaneous injection; strength and presentation set by the prescription | Unverified |
| Dosing | Fixed by the FDA label | Set by the prescribing provider | No prescriber at all |
| How you get it | Prescription from a clinician, filled by a pharmacy | Provider evaluation, then a licensed pharmacy fills it | Online sellers, no prescription |
What the Vyleesi label actually says
The current Vyleesi prescribing information on DailyMed is narrower than most online summaries suggest.
- Indication: premenopausal women with acquired, generalized HSDD, meaning low desire that causes marked distress or interpersonal difficulty and is not due to another medical or psychiatric condition, relationship problems, or a medication.
- Limitations of use: not indicated for HSDD in postmenopausal women or in men, and not indicated to enhance sexual performance.
- Label dosing: 1.75 mg injected under the skin of the abdomen or thigh, as needed, at least 45 minutes before anticipated sexual activity. No more than one dose within 24 hours, and more than 8 doses per month is not recommended.
- Contraindications: uncontrolled hypertension or known cardiovascular disease.
Those numbers describe the approved branded product. They are not instructions for compounded PT-141, where the prescribing provider sets the dose. The approval rested on the two phase 3 RECONNECT trials, which reported statistically significant improvements in desire and in distress about low desire versus placebo in premenopausal women with HSDD. Nausea, flushing and headache were the most common side effects, and the 52-week extension reported nausea in 40.4%, flushing in 20.6% and headache in 12.0% of participants.
Where compounded PT-141 fits
Compounding is the preparation of a medicine by a licensed pharmacy for an individual patient, against a prescription. The FDA is direct about the trade-off: compounded drugs are not FDA-approved, which means the FDA does not verify their safety, effectiveness or quality before they are marketed.
So "same molecule" does not mean "same product". Compounded PT-141 can differ from Vyleesi in concentration, container and dosing. What it does share with Vyleesi is a prescriber, a pharmacy label with your name on it, and a route back to a clinician if something feels wrong. Research-grade vials have none of those. The sourcing difference is unpacked in compounded vs research-grade PT-141.
One more practical difference: an intranasal form of bremelanotide was studied but never reached approval because of blood-pressure findings. Subcutaneous injection is the route that was approved, and it is the route telos rx prescribes. telos rx does not offer a nasal spray. See PT-141 nasal spray vs injection for the background.
Not sure which of these fits your situation? A short online visit lets a licensed provider review your history without a scheduled appointment, and you pay nothing if you are not approved.
See if PT-141 is right for youWho each option is generally for
This is general orientation, not a self-diagnosis tool. The final call belongs to a clinician who knows your history.
Premenopausal women with diagnosed HSDD
This is the one group Vyleesi is approved for, and the group the phase 3 evidence describes. If that matches you, it is reasonable to ask your own clinician about the branded product as well as compounded options. Our PT-141 for women and HSDD guide explains what the diagnosis requires.
Postmenopausal women and men
Vyleesi's label excludes both groups. Bremelanotide use in men is off-label, and the evidence in men is earlier-phase. Some providers may consider compounded PT-141 off-label after a full review, and others will not. See PT-141 for men for what the research does and does not show.
People with uncontrolled blood pressure or heart disease
Bremelanotide can cause a transient rise in blood pressure, and the trials excluded people with uncontrolled hypertension or known cardiovascular disease. That applies to the molecule, so it applies whichever product name is on the box. More in who should not take PT-141.
How each one is obtained
- Vyleesi: a clinician prescribes it for the approved indication, and a pharmacy dispenses the autoinjectors. Pricing and coverage vary, so check directly with your pharmacy or insurer rather than relying on figures quoted online.
- Compounded PT-141: a licensed provider evaluates you, and if appropriate, writes a prescription that a licensed pharmacy prepares and labels for you.
- Research-grade PT-141: not a legitimate route. These products are sold with no prescriber and no way to confirm identity, strength or sterility, which matters a great deal for anything injected.
Before you buy from anyone, our guides on how to buy PT-141 online safely and how to verify a pharmacy walk through the checks.
Questions worth asking before you choose
- Does my situation fall inside the Vyleesi indication, or would any use be off-label?
- Is my blood pressure well controlled, and is there any heart history the prescriber needs to know?
- Who prepares the medication, and is that pharmacy licensed?
- Who sets the dose, and how do I reach that person if I have side effects such as nausea?
- Do any of my current medications interact? See PT-141 drug interactions.
How telos rx prescribes compounded PT-141
telos rx prescribes compounded PT-141 as a small, as-needed subcutaneous injection given at home before anticipated activity. You can see the details on the PT-141 page.
- One online intake for adults of any sex, reviewed asynchronously by a licensed provider, with no scheduled appointment.
- Every prescription is subject to medical approval by a licensed provider. If you are not approved, you pay nothing.
- Filled by licensed US partner pharmacies, with free, discreet shipping.
- As low as $138 per month, FSA/HSA eligible, cancel anytime. telos rx is LegitScript-certified.
Compounded PT-141 is not FDA-approved. If your provider thinks the branded product or a different approach fits you better, they will say so.
Frequently asked questions
Is bremelanotide the same as Vyleesi?
Bremelanotide is the active molecule, and Vyleesi is the FDA-approved branded autoinjector that contains it. Vyleesi is approved only for acquired, generalized HSDD in premenopausal women.
Is compounded PT-141 the same as Vyleesi?
It contains the same active molecule, bremelanotide, but it is not the same product. Compounded PT-141 is prepared by a licensed pharmacy for an individual prescription, is not FDA-approved, and its strength and dosing are set by the prescribing provider.
What is PT-141?
PT-141 is the development code name for bremelanotide, a melanocortin receptor agonist that acts in the brain rather than on blood flow. Today the name is mostly used for compounded preparations.
Is Vyleesi approved for men?
No. The Vyleesi label states it is not indicated for HSDD in men or in postmenopausal women. Any bremelanotide use in men is off-label and is a decision for a licensed provider.
Why would someone use compounded PT-141 instead of Vyleesi?
Usually because their situation falls outside the Vyleesi indication, or because a provider prefers a different presentation or dose. Compounded PT-141 is not FDA-approved, so the choice should be made with a licensed provider.
Is research-grade PT-141 the same as compounded PT-141?
No. Research-grade products are sold as not for human use, with no prescriber and no way to confirm identity, strength or sterility. Compounded PT-141 is prepared by a licensed pharmacy for a named patient against a prescription.
The right product depends on your history, not the name on a search result. Start a short online visit and a licensed provider will decide whether compounded PT-141 fits you.
Start your online visitThis article is for general education and is not medical advice. Compounded PT-141 is not FDA-approved and has not been evaluated by the FDA for safety, effectiveness or quality. Vyleesi is FDA-approved only for acquired, generalized HSDD in premenopausal women; other uses, including use in men, are off-label. All prescriptions are subject to medical approval by a licensed provider; approval is not guaranteed. Individual experiences vary. telos rx is an online-first, asynchronous telehealth service and is LegitScript-certified. Medications are filled by licensed US partner pharmacies.